Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
QuintilesIMS
Fish and Richardson
Teva
Argus Health
McKesson
Accenture
Chubb
Johnson and Johnson

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PONATINIB HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Ponatinib Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00660920 Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies Active, not recruiting Ariad Pharmaceuticals Phase 1 The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule (QD) in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.
NCT01207440 Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) Active, not recruiting Ariad Pharmaceuticals Phase 2 The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation.
NCT01424982 Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting Ariad Pharmaceuticals Phase 2 The goal of this clinical research study is to learn if intensive chemotherapy combined with ponatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied. Ponatinib may cause a blood clot to form in an artery or in a vein. Depending on the location of the clot, this could cause a heart attack, a stroke, severe damage to other tissue, or death. A blood clot may occur within 2 weeks after you start taking the drug. About 25% (1 in 4) of patients taking the drug form an abnormal clot. Blood clots can occur in patients that do not have other known risk factors for forming clots. If you develop a blood clot, you will need to stop taking ponatinib. In some cases, emergency surgery could be needed to remove the clot and restore blood flow.
NCT01424982 Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) Recruiting M.D. Anderson Cancer Center Phase 2 The goal of this clinical research study is to learn if intensive chemotherapy combined with ponatinib, followed by maintenance therapy, can help to control ALL with the Ph chromosome and/or BCR-ABL. The safety of this treatment will also be studied. Ponatinib may cause a blood clot to form in an artery or in a vein. Depending on the location of the clot, this could cause a heart attack, a stroke, severe damage to other tissue, or death. A blood clot may occur within 2 weeks after you start taking the drug. About 25% (1 in 4) of patients taking the drug form an abnormal clot. Blood clots can occur in patients that do not have other known risk factors for forming clots. If you develop a blood clot, you will need to stop taking ponatinib. In some cases, emergency surgery could be needed to remove the clot and restore blood flow.
NCT01549548 Compassionate Use Ponatinib No longer available Ariad Pharmaceuticals N/A The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ponatinib Hydrochloride

Condition Name

Condition Name for Ponatinib Hydrochloride
Intervention Trials
Leukemia 6
Chronic Myeloid Leukemia 6
Acute Lymphoblastic Leukemia 3
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ponatinib Hydrochloride
Intervention Trials
Leukemia 24
Leukemia, Myeloid 17
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15
Precursor Cell Lymphoblastic Leukemia-Lymphoma 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ponatinib Hydrochloride

Trials by Country

Trials by Country for Ponatinib Hydrochloride
Location Trials
United States 124
Japan 14
Australia 11
France 10
Canada 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ponatinib Hydrochloride
Location Trials
Texas 14
Oregon 9
Massachusetts 7
Maryland 7
Michigan 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ponatinib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Ponatinib Hydrochloride
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 19
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ponatinib Hydrochloride
Clinical Trial Phase Trials
Recruiting 21
Terminated 4
Active, not recruiting 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ponatinib Hydrochloride

Sponsor Name

Sponsor Name for Ponatinib Hydrochloride
Sponsor Trials
Ariad Pharmaceuticals 16
M.D. Anderson Cancer Center 8
National Cancer Institute (NCI) 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ponatinib Hydrochloride
Sponsor Trials
Other 29
Industry 20
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Colorcon
Accenture
Cantor Fitzgerald
McKesson
Boehringer Ingelheim
Medtronic
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.